Akiyama N, Mori T, Kusaba R, Inou T, Hamajima K
Jpn J Exp Med. 1978 Aug;48(4):321-5.
In order to examine the presence of antibodies against B cells, 83 sera obtained from 55 renal transplant recipients were screened by microcytotoxicity test using Daudi cell line. Out of 83 samples, 12 were pretransplant sera, 62 were post-transplant sera and 9 were from the patients whose grafts has been removed due to rejection. For the purpose of improving the reliability of the tests, 5 different rabbit complements were selected and cytotoxicity tests with them were carried out simultaneously. Pretransplant sera without blood transfusion did not show any cytotoxicity against Daudi cells. Although 42% of post-transplant sera showed cytotoxicity against Daudi cells, cytotoxic activity of the sera showed no relation with the occurrence of rejection episodes. Three serum samples out of 5 patients whose grafts had been removed due to rejection showed strong cytotoxicity against Daudi cells and the sera of 2 other patients did not. There was no relation between the cytotoxicity against Daudi cells and antibodies against Epstein-Barr virus capsid antigen in the post-transplant sera.
为检测抗B细胞抗体的存在情况,使用Daudi细胞系通过微量细胞毒性试验对55例肾移植受者的83份血清进行了筛查。83份样本中,12份为移植前血清,62份为移植后血清,9份来自因排斥反应而切除移植物的患者。为提高检测的可靠性,选择了5种不同的兔补体,并同时用它们进行细胞毒性试验。未输血的移植前血清对Daudi细胞未显示任何细胞毒性。虽然42%的移植后血清对Daudi细胞显示细胞毒性,但血清的细胞毒性活性与排斥反应发作的发生无关。5例因排斥反应而切除移植物的患者中,有3份血清样本对Daudi细胞显示出强细胞毒性,另外2例患者的血清则未显示。移植后血清中对Daudi细胞的细胞毒性与抗EB病毒衣壳抗原抗体之间没有关系。